Growth Hormone and the Transition from Puberty into Adulthood

Endocrinology and Metabolism Clinics of North America

Volumn 36, Issue 1, 2007, Pages 187-201

  Attanasio, Andrea F ^a   Shalet, Stephen M ^b  

^a Cascina del Rosone   (Italy)

^b CHRISTIE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH HORMONE;

ADULTHOOD; ALGORITHM; BODY BUILD; BODY COMPOSITION; BODY HEIGHT; BODY MASS; BONE DENSITY; BONE MASS; CARDIOVASCULAR RISK; CLINICAL FEATURE; CLINICAL TRIAL; DRUG WITHDRAWAL; DUAL ENERGY X RAY ABSORPTIOMETRY; DYSLIPIDEMIA; FAT BODY; GROWTH HORMONE DEFICIENCY; HORMONAL THERAPY; HORMONE SUBSTITUTION; HUMAN; LEAN BODY WEIGHT; MORPHOMETRICS; MUSCLE MASS; OBESITY; OUTCOMES RESEARCH; PRACTICE GUIDELINE; PRIORITY JOURNAL; PUBERTY; QUALITATIVE ANALYSIS; QUALITY OF LIFE; QUANTITATIVE ANALYSIS; REVIEW; SPINE; TREATMENT DURATION;

AGING; BODY HEIGHT; DWARFISM, PITUITARY; GROWTH HORMONE; HORMONE REPLACEMENT THERAPY; HUMANS; PUBERTY; WITHHOLDING TREATMENT;

EID: 33847254365     PISSN: 08898529     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ecl.2006.11.002     Document Type: Review

References (44)

1. Attanasio A.F., Lamberts S.W.J., Matranga A.M.C., et al. Adult growth hormone (GH)-deficient patients demonstrate heterogeneity between childhood onset and adult onset before and during human GH treatment. J Clin Endocrinol Metab 82 (1997) 82-88
2. De Boer H., and van der Veen E.A. Why retest young adults with childhood-onset growth deficiency?. J Clin Endocrinol Metab 82 (1997) 2032-2036
3. Clayton P.E., Cuneo R.C., Juul A., et al. Consensus statement on the management of the GH-treated adolescent in the transition to adult care. Eur J Endocrinol 152 (2005) 165-170
4. Theintz G., Buchs B., Rizzoli R., et al. Longitudinal monitoring of bone mass accumulation in healthy adolescents: evidence for a marked reduction after 16 years of age at the levels of lumbar spine and femoral neck in female subjects. J Clin Endocrinol Metab 75 (1992) 1060-1065
5. Rizzoli R., and Bonjour J.P. Determinants of peak bone mass and mechanisms of bone loss. Osteoporos Int 9 Suppl 2 (1999) 17-23
6. Ngyuen T.V., Maynard L.M., Towne B., et al. Sex differences in bone mass acquisition during growth: the Fels Longitudinal Study. J Clin Densitom 4 (2001) 147-157
7. Guo S.S., Chumlea W.C., Roche A.F., et al. Age- and maturity-related changes in body composition during adolescence into adulthood: the Fels Longitudinal Study. Int J Obes Relat Metab Disord 21 (1997) 1167-1175
8. Forbes G.B. Relation of lean body mass to height in children and adolescents. Pediatr Res 6 (1972) 32-37
9. Barlett H.L., Puhl S.M., Hodgson J.L., et al. Fat-free mass in relation to stature: ratios of fat-free mass to height in children, adults, and elderly subjects. Am J Clin Nutr 53 (1991) 1112-1116
10. Forbes G.B. Body composition in adolescence. Prog Clin Biol Res 61 (1981) 55-72
11. Zadik Z., Chalew S.A., McCarter Jr. R.J., et al. The influence of age on the 24-hour integrated concentration of growth hormone in normal individuals. J Clin Endocrinol Metab 605 (1985) 513-516
12. Blum W.F., and Breier B.H. Radioimmunoassays for IGFs and IGFBPs. Growth Regul 4 (1994) 11-19
13. Attanasio A.F., Howell S., Bates P.C., et al. Body composition, IGF-I and IGFBP-3 concentrations as outcome measures in severely GH-deficient (GHD) patients after childhood GH treatment: a comparison with adult onset GHD patients. J Clin Endocrinol Metab 87 (2002) 3368-3372
14. Lissett C.A., Jonsson P., Monson J.P., et al. Determinants of IGF-I status in a large cohort of growth hormone-deficient (GHD) subjects: the role of timing of onset of GHD. Clin Endocrinol (Oxf) 59 (2003) 773-778
15. Rutherford O.M., Jones D.A., Round J.M., et al. Changes in skeletal muscle after discontinuation of growth hormone treatment in growth hormone deficient young adults. Clin Endocrinol (Oxf) 34 (1991) 469-475
16. Ogle G.D., Moore B., Lu P.W., et al. 1994 Changes in body composition and bone density after discontinuation of growth hormone therapy in adolescence: an interim report. Acta Paediatr Suppl 399 (1994) 3-7
17. Johannsson G., Albertsson-Wikland K., and Bengtsson B.-A. Discontinuation of growth hormone (GH) treatment: metabolic effects in GH-deficient and GH-sufficient adolescent patients compared with control subjects. J Clin Endocrinol Metab 84 (1999) 4516-4524
18. Shalet S.M., Shavrikova E., Cromer M., et al. Effect of growth hormone (GH) treatment on bone in postpubertal GH-deficient patients: a 2-year randomized, controlled, dose-ranging study. J Clin Endocrinol Metab 88 (2003) 4124-4129
19. Tauber M., Jouret B., Cartault A., et al. Adolescents with partial growth hormone (GH) deficiency develop alterations of body composition after GH discontinuation and require follow-up. J Clin Endocrinol Metab 88 (2003) 5101-5106
20. Rosén T., and Bengtsson B.-A. Premature mortality due to cardiovascular diseases in hypopituitarism. Lancet 336 (1990) 285-288
21. Bülow B., Hagmar L., Mikoczy Z., et al. Increased cerebrovascular mortality in patients with hypopituitarism. Clin Endocrinol (Oxf) 46 (1997) 75-81
22. DeBoer H., Blok C.J., and Van der Veen E.A. Clinical aspects of growth hormone deficiency in adults. Endocr Rev 16 (1995) 63-86
23. Clayton P.E., Price D.A., and Shalet S.M. Growth hormone state after completion of treatment with growth hormone. Arch Dis Child 62 (1987) 222-226
24. Cacciari E., Tassoni P., Parisi G., et al. Pitfalls in diagnosing impaired growth hormone (GH) secretion: retesting after replacement therapy of 63 patients defined as GH deficient. J Clin Endocrinol Metab 74 (1992) 1284-1289
25. Wacharasindhu S., Cotterill A.M., Camacho-Hubner E., et al. Normal growth hormone secretion in growth hormone insufficient children retested after completion of linear growth. Clin Endocrinol (Oxf) 45 (1996) 553-556
26. Longobardi S., Merola B., Pivonello R., et al. Re-evaluation of growth hormone (GH) secretion in 69 adults diagnosed as GH deficient patients during childhood. J Clin Endocrinol Metab 81 (1996) 1244-1247
27. Nicolson A., Toogood A.A., Rahim A., et al. The prevalence of severe growth hormone deficiency in adults who received growth hormone replacement in childhood. Clin Endocrinol (Oxf) 44 (1996) 311-316
28. Tauber M., Moulin P., Pienkowski C., et al. Growth hormone (GH) retesting and auxological data in 131 GH-deficient patients after completion of treatment. J Clin Endocrinol Metab 82 (1997) 352-356
29. Juul A., Kastrup K.W., Pedersen S.A., et al. Growth hormone (GH) provocative retesting of 108 young adults with childhood-onset GH deficiency and the diagnostic value of insulin-like growth factor 1 (IGF-I) and IGF-binding protein-3. J Clin Endocrinol Metab 82 (1997) 1195-1201
30. Attanasio A.F., Howell S., Bates P.C., et al. Confirmation of severe GH deficiency after final height in patients diagnosed as GH deficient during childhood. Clin Endocrinol (Oxf) 56 (2002) 503-507
31. Growth Hormone Research Society. Consensus guidelines for the diagnosis and treatment of adults with growth hormone deficiency: summary statement of the Growth Hormone Research Society workshop on adult growth hormone deficiency. J Clin Endocrinol Metab 83 (1998) 379-381
32. Nørrelund H., Vahl N., Juul A., et al. Continuation of growth hormone (GH) therapy in GH-deficient patients during transition from childhood to adulthood: impact on insulin sensitivity and substrate metabolism. J Clin Endocrinol Metab 85 (2000) 1912-1917
33. Underwood L.E., Attie K.M., Baptista J., et al. Growth hormone (GH) dose-response in young adults with childhood-onset GH deficiency: a two-year, multicenter, multiple-dose, placebo-controlled study. J Clin Endocrinol Metab 88 (2003) 5273-5280
34. Mauras N., Pescovitz O.H., Allada V., et al. Limited efficacy of growth hormone (GH) during transition of GH-deficient patients from adolescence to adulthood: a phase III multicenter, double-blind, randomized two-year trial. J Clin Endocrinol Metab 90 (2005) 3946-3955
35. Vahl N., Juul A., Jørgensen J.O.L., et al. Continuation of growth hormone (GH) replacement in GH-deficient patients during transition from childhood to adulthood: a two-year placebo-controlled study. J Clin Endocrinol Metab 85 (2000) 1874-1881
36. Attanasio A.F., Shavrikova E., Blum W.F., et al. Continued growth hormone (GH) treatment after final height is necessary to complete somatic development in childhood-onset GH-deficient patients. J Clin Endocrinol Metab 89 (2004) 4857-4862
37. Murray R.D., Columb B., Adams J.E., et al. Low bone mass is an infrequent feature of the adult growth hormone deficiency syndrome in middle-age adults and the elderly. J Clin Endocrinol Metab 89 (2004) 1124-1130
38. Murray R.D., Adams J.E., and Shalet S.M. A densitometric and morphometric analysis of the skeleton in adults with varying degrees of growth hormone deficiency. J Clin Endocrinol Metab 91 (2005) 432-438
39. Bouillon R., Koledova E., Bezlepkina O., et al. Bone status and fracture in Russian adults with childhood-onset growth hormone deficiency. J Clin Endocrinol Metab 89 (2004) 4993-4998
40. Drake W.M., Carroll P.V., Maher K.T., et al. The effect of cessation of growth hormone (GH) therapy on bone mineral accretion in GH-deficient adolescents at the completion of linear growth. J Clin Endocrinol Metab 88 (2005) 1658-1663
41. Caprio S., Plewe G., Diamond M.P., et al. Increased insulin secretion in puberty: a compensatory response to reductions in insulin sensitivity. J Pediatr 114 (1989) 963-967
42. Caprio S., Boulware D., and Tamborlane W. Growth hormone and insulin interactions. Horm Res 38 Suppl 2 (1992) 47-49
43. Murray RD, Skillicorn CJ, Howell SJ, et al. Influences on quality of life in GH deficient adults and their effect on response to treatment. Clin Endocrinol 1999;51:565-73.
44. Attanasio A.F., Shavrikova E.P., Blum W.F., et al. Quality of life in childhood onset growth hormone deficient patients in the transition phase from childhood to adulthood. J Clin Endocrinol Metab 90 (2005) 4525-4529